Switch theme
Sign up to access all valuation multiples
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
2007
62
LTM Revenue $249M
LTM EBITDA $53.2M
$497M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Atrys Health has a last 12-month revenue (LTM) of $249M and a last 12-month EBITDA of $53.2M.
In the most recent fiscal year, Atrys Health achieved revenue of $239M and an EBITDA of $21.4M.
Atrys Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Atrys Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $249M | XXX | $239M | XXX | XXX | XXX |
| Gross Profit | $166M | XXX | $163M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $53.2M | XXX | $21.4M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $11.2M | XXX | $11.7M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | -$18.8M | XXX | -$35.7M | XXX | XXX | XXX |
| Net Margin | -8% | XXX | -15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $229M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Atrys Health's stock price is EUR 3 (or $3).
Atrys Health has current market cap of EUR 208M (or $234M), and EV of EUR 443M (or $497M).
See Atrys Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $497M | $234M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Atrys Health has market cap of $234M and EV of $497M.
Atrys Health's trades at 2.1x EV/Revenue multiple, and 23.2x EV/EBITDA.
Equity research analysts estimate Atrys Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atrys Health has a P/E ratio of -12.4x.
See valuation multiples for Atrys Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $234M | XXX | $234M | XXX | XXX | XXX |
| EV (current) | $497M | XXX | $497M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 23.2x | XXX | XXX | XXX |
| EV/EBIT | 44.4x | XXX | 42.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.4x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | 51.8x | XXX | -43.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtrys Health's last 12 month revenue growth is 7%
Atrys Health's revenue per employee in the last FY averaged $3.9M, while opex per employee averaged $2.4M for the same period.
Atrys Health's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atrys Health's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Atrys Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atrys Health acquired XXX companies to date.
Last acquisition by Atrys Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Atrys Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Atrys Health founded? | Atrys Health was founded in 2007. |
| Where is Atrys Health headquartered? | Atrys Health is headquartered in Spain. |
| How many employees does Atrys Health have? | As of today, Atrys Health has 62 employees. |
| Who is the CEO of Atrys Health? | Atrys Health's CEO is Ms. Isabel Lozano Fernandez. |
| Is Atrys Health publicy listed? | Yes, Atrys Health is a public company listed on MAD. |
| What is the stock symbol of Atrys Health? | Atrys Health trades under ATRY ticker. |
| When did Atrys Health go public? | Atrys Health went public in 2016. |
| Who are competitors of Atrys Health? | Similar companies to Atrys Health include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Atrys Health? | Atrys Health's current market cap is $234M |
| What is the current revenue of Atrys Health? | Atrys Health's last 12 months revenue is $249M. |
| What is the current revenue growth of Atrys Health? | Atrys Health revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Atrys Health? | Current revenue multiple of Atrys Health is 2.0x. |
| Is Atrys Health profitable? | Yes, Atrys Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Atrys Health? | Atrys Health's last 12 months EBITDA is $53.2M. |
| What is Atrys Health's EBITDA margin? | Atrys Health's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Atrys Health? | Current EBITDA multiple of Atrys Health is 9.4x. |
| What is the current FCF of Atrys Health? | Atrys Health's last 12 months FCF is $9.6M. |
| What is Atrys Health's FCF margin? | Atrys Health's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Atrys Health? | Current FCF multiple of Atrys Health is 51.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
